Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathway

Circulation Journal

Volumn 77, Issue 12, 2013, Pages 2997-3006

  Song, Bei ^a,b   Zhang, Zhen Zhou ^a,b,d   Zhong, Jiu Chang ^a,b   Yu, Xi Yong ^c   Oudit, Gavin Y ^d   Jin, Hai Yan ^a   Lu, Lin ^a   Xu, Ying Le ^a,b   Kassiri, Zamaneh ^d   Shen, Wei Feng ^a   Gao, Ping Jin ^a,b   Zhu, Ding Liang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Institute of Hypertension   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin converting enzyme 2; Connective tissue growth factor; Fractalkine; Matrix metalloproteinase; Myocardial injury

Indexed keywords

ANGIOTENSIN [1-7] [7 DEXTRO ALANINE]; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; FRACTALKINE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMOOTH MUSCLE ACTIN; SUPEROXIDE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANGIOTENSIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART CELL CULTURE; HEART DISEASE; HEART MUSCLE INJURY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY;

ANGIOTENSIN II; ANIMALS; CHEMOKINE CX3CL1; CONNECTIVE TISSUE GROWTH FACTOR; GENE EXPRESSION REGULATION; HEART INJURIES; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; PHOSPHORYLATION; VASOCONSTRICTOR AGENTS;

EID: 84888263688     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0805     Document Type: Article

References (34)

1. Wang M, Zhang J, Walker SJ, Dworakowski R, Lakatta EG, Shah AM. Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol 2010; 48: 765-772.
2. Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ J 2013; 77: 301-308.
3. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fbrosis, and cardiac dysfunction. Circulation 2010; 122: 717-728.
4. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556.
5. Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, et al. Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fbrosis. Hypertension 2009; 54: 575-582.
6. Ebrahimian T, Li MW, Lemarié CA, Simeone SM, Pagano PJ, Gaestel M, et al. Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced infammation and hypertension: Regulation of oxidative stress. Hypertension 2011; 57: 245-254.
7. Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overex-pression in the paraventricular nucleus attenuates angiotensin II-in-duced hypertension. Cardiovasc Res 2011; 92: 401-408.
8. Bodiga S, Zhong JC, Wang W, Basu R, Lo J, Liu GC, et al. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc Res 2011; 91: 151-161.
9. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et al. Angiotensin II-mediated oxidative stress and infammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardio-vasc Res 2007; 75: 29-39.
10. Wu SH, Lu C, Dong L, Chen ZQ. Signal transduction involved in CTGF-induced production of chemokines in mesangial cells. Growth Factors 2008; 26: 192-200.
11. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2009; 2: 446-455.
12. Ko WC, Hong CY, Hou SM, Lin CH, Ong ET, Lee CF, et al. Elevated expression of connective tissue growth factor in human atrial f-brillation and angiotensin II-treated cardiomyocytes. Circ J 2011; 75: 1592-1600.
13. Wu W, Muchir A, Shan J, Bonne G, Worman HJ. Mitogen-activated protein kinase inhibitors improve heart function and prevent fbrosis in cardiomyopathy caused by mutation in lamin A/C gene. Circulation 2011; 123: 53-61.
14. Higuchi K, Nakaoka Y, Shioyama W, Arita Y, Hashimoto T, Yasui T, et al. Endothelial Gab1 deletion accelerates angiotensin II-depen-dent vascular infammation and atherosclerosis in apolipoprotein E knockout mice. Circ J 2012; 76: 2031-2040.
15. Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling. Hypertension 2012; 60: 137-144.
16. Patel VB, Bodiga S, Fan D, Das SK, Wang Z, Wang W, et al. Cardio-protective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angio-tensin-converting enzyme 2-null mice. Hypertension 2012; 59: 1195-1203.
17. Jin HY, Song B, Oudit GY, Davidge ST, Yu HM, Jiang YY, et al. ACE2 defciency enhances angiotensin II-mediated aortic proflin-1 expression, infammation and peroxynitrite production. PLoS One 2012; 7: e38502, doi:10.1371/journal.pone.0038502.
18. Murça TM, Moraes PL, Capuruço CA, Santos SH, Melo MB, Santos RA, et al. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept 2012; 177: 107-115.
19. Zhong JC, Ye JY, Jin HY, Yu X, Yu HM, Zhu DL, et al. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and proflin-1 expression. Regul Pept 2011; 166: 90-97.
20. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, et al. Prevention of angiotensin II-mediated renal oxidative stress, infammation, and fbrosis by angiotensin-converting enzyme 2. Hypertension 2011; 57: 314-322.
21. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxi-dase-derived reactive oxygen species. Circ Res 2003; 92: e80-e86, doi:10.1161/01. RES.0000077044.60138.7C.
22. Leask A. Potential therapeutic targets for cardiac fbrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fbroblast activation. Circ Res 2010; 106: 1675-1680.
23. Panek AN, Posch MG, Alenina N, Ghadge SK, Erdmann B, Popova E, et al. Connective tissue growth factor overexpression in cardio-myocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One 2009; 4: e6743, doi:10.1371/journal.pone. 0006743.
24. Xuan W, Liao Y, Chen B, Huang Q, Xu D, Liu Y, et al. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 2011; 92: 385-393.
25. Finckenberg P, Eriksson O, Baumann M, Merasto S, Lalowski MM, Levijoki J, et al. Caloric restriction ameliorates angiotensin II-in-duced mitochondrial remodeling and cardiac hypertrophy. Hypertension 2012; 59: 76-84.
26. Haack KK, Gao L, Schiller AM, Curry PL, Pellegrino PR, Zucker IH. Central rho kinase inhibition restores barorefex sensitivity and angiotensin ii type 1 receptor protein imbalance in conscious rabbits with chronic heart failure. Hypertension 2013; 61: 723-729.
27. Schiffrin EL. Vascular remodeling in hypertension: Mechanisms and treatment. Hypertension 2012; 59: 367-374.
28. Zhang ZZ, Shang QH, Jin HY, Song B, Oudit GY, Lu L, et al. Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-defcient mice. J Transl Med 2013; 11: 229.
29. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. Prevention of angiotensin II-induced cardiac remodeling by an-giotensin-(1-7). Am J Physiol Heart Circ Physiol 2007; 292: H736-H742.
30. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 2008; 103: 1319-1326.
31. Gava E, de Castro CH, Ferreira AJ, Colleta H, Melo MB, Alenina N, et al. Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart. Regul Pept 2012; 175: 30-42.
32. Song B, Jin H, Yu X, Zhang Z, Yu H, Ye J, et al. Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and proflin-1/MAPK signaling pathways. Regul Pept 2013; 185: 44-51.
33. Caruso R, Caselli C, Boroni C, Campolo J, Milazzo F, Cabiati M, et al. Relationship between myocardial redox state and matrix metal-loproteinase activity in patients on left ventricular assist device support. Circ J 2011; 75: 2387-2396.
34. Cao H, Wang J, Xi L, Røe OD, Chen Y, Wang D. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fbrillation. Circ J 2011; 75: 2781-2788.